<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">O'Byrne, Ken J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Systemic Treatment for Advanced NSCLC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">29-30</style></pages><abstract><style  face="normal" font="default" size="100%">The recent understanding of the relation between the cancer cell and the immune system includes a knowledge of how the cancer cell produces proteins that prevent the immune system from recognizing and killing the cancer cell, as well as the identification of a series of inhibitory receptors, activating receptors, and other pathways. This understanding is advancing the field of systemic immune therapy for oncology. Non-small cell lung cancer (NSCLC) is a heterogeneous disease with numerous driver mutations. This article discusses new insights into immune privilege, improved diagnosis, as well as the need for drugs to overcome secondary resistance to systemic treatment.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>